Anthropic Launches AI Drug Discovery Program

Anthropic has unveiled Claude Science, an AI workbench tailored for biopharmaceutical research, and announced its entry into drug discovery, focusing on neglected diseases.

Claude Science: AI Workbench for Biopharma

Claude Science integrates databases, lab tools, and computing power to automate and accelerate drug discovery processes. It's designed to reduce operational delays and enhance research efficiency.

Direct Entry into Drug Discovery

Anthropic is initiating its own drug discovery programs targeting neglected diseases, leveraging its AI platforms and recent acquisitions to develop new therapeutics.

Do you want to see how to make more plays? Do you want to find gains yourself?

Unusual Whales helps you find market opportunities through our market tide, historical options flow, GEX, and much, much more.

Create a free account here to start conquering the market with Unusual Whales.

Strategic Acquisitions

In April 2026, Anthropic acquired Coefficient Bio, a stealth AI drug discovery startup, in an all-stock deal valued at approximately $400 million. This acquisition bolsters Anthropic's capabilities in the pharmaceutical sector.

Partnerships Enhancing AI Capabilities

Inductive Bio has joined Anthropic's life sciences ecosystem, launching a connector that integrates its ADMET prediction models directly within Claude. This collaboration aims to democratize AI-powered drug discovery by providing scientists with advanced predictive tools.

Options Market and Stocks to Watch

Watch for potential impacts on pharmaceutical companies like Eli Lilly (LLY), Pfizer (PFE), and Merck (MRK) as AI integration in drug discovery evolves.

Want more market intelligence? Create your free Unusual Whales account for options flow, market tide, GEX, and the full toolkit.